Propionylpromazine: Unveiling a Novel Inhibitory Agent AgainstMycobacterium tuberculosis

Abstract

ABSTRACTThe emergence of multidrug-resistantmycobacterium tuberculosispresents a significant hurdle, as it shows resistance to existing standard therapies, underscoring the critical need for novel antibacterial agents. This study presents propionylpromazine as a promising compound with potent activity againstM. tuberculosis. Our research indicates that propionylproma zine effectively curtails the proliferation ofM. tuberculosisH37Rv. Importantly, propionylpromazine has shown the capability to impede the growth ofM. tuberculosiswithin macrophages without causing detrimental effects. These findings endorse the potential of propionylpromazine to be further developed as a clinical drug for the effective treatment ofM. tuberculosisinfections.